Observations on the Tyco verdict

tyco.jpgThe morning brings several interesting obserations regarding yesterday’s guilty verdict in the trial of former Tyco International, Ltd. executives, L. Dennis Kozlowski and former Tyco finance chief Mark H. Swartz.
Over at Conglomerate, Professor Hurt (a former Houstonian, by the way) notes insightfully in this post that, on one hand, the case against Messrs. Kozlowski and Swartz differs from most other corporate crime prosecutions because of its relative simplicity, but that — on the other hand — such simplicity insures that no amount of regulation will ever prevent such actions from occurring again.
Meanwhile, over at the White Collar Crime Prof Blog, Professor Henning makes a key technical point about the way in which the prosecution handled the more recent prosecution after the first trial ended in a mistrial:

The government made its case in about 25% less time (13 weeks as opposed to 18 weeks in the first trial), and kept the accounting and reporting issues front-and-center. Going technical is usually a recipe for disaster (see the Enron Broadband Services prosecution for an example of mind-numbing detail), but in this case the Manhattan D.A.’s office concentrated on what was truly important.

Finally, in this remarkable analysis, Professor Ribstein questions the wisdom of unleashing the power of the state based upon the human frailties that drive most prosecutions of questionable business conduct:

Not merely envy (one’s discomfort at comparing oneself with another), or wanting to have what another person has, but disliking that person for having it and believing that his good fortune is undeserved. The resenter wants to lower the envied person to his level.
This is the common element in Tyco, Martha Stewart, Mike Milken and many other cases of this ilk, despite the facial dissimilarity of the offenses being tried.
Resentment is pernicious enough in itself because it seeks to degrade human achievement. But it’s worse when it leads to criminal prosecutions for what amount to agency costs — failure to get the requisite corporate approval for expenditures. The marginal criminality of these offenses is what leads to months of hugely expensive trials.
The supposed social payoff is deterrence. But the Kozlowskis of the world probably will keep doing this stuff while the legitimate sorts will be ever more afraid of taking chances. Not that the conduct in Tyco was particularly worth encouraging, but Mike Milken was a different case, in my view, and I don’t see much chance of politically ambitious prosecutors being able or willing to tell the difference.
So white collar prosecutions become a sort of lottery. If the prosecution can come up with something colorful, it wins, or maybe loses if it’s too colorful (Sardinia). These are not the elements of a rational criminal justice system.

Nor is it rational to base corporate criminal prosecutions on the timing of going bust.

The Lord does not enjoy competition in the regulation market

Spitzer23.jpgFollowing on the heels of this earlier post, this NY Times article reports on the lawsuits that the Office of the Comptroller of the Currency and the Clearing House Association filed on Thursday in Manhatten U.S. District Court to enjoin the Lord of Regulation from using his subpoena power to obtain nonpublic credit score and loan information from national banks such as HSBC Holdings, J. P. Morgan and Wells Fargo. Here is an earlier post on Mr. Spitzer’s latest attempt to injure a productive part of the national economy, this time the sub-prime mortgage market.
Not pleased with competition in the regulation market that infringes on his demagogic ways, Mr. Spitzer commented as follows about the lawsuits:

“While such a move was expected from the banks, it is shameful that a federal regulator would join in an effort to shield the banks from scrutiny by state regulators.”

To which I wish the Comptroller of the Currency would respond:

“While we understand that Mr. Spitzer enjoys undertaking investigations that will provide publicity for his political purposes, we do not expect him to undertake investigations into areas that are the province of federal regulation and that will harm the ability of low-income families to climb the ladder to prosperity through home ownership.”

New Chron blog reports on medical research funds

medical research.jpgThe Houston Chronicle has added another blog — Eric Berger’s SciGuy — to its impressive and expanding Chronicle bloglist that Chronicle tech writer Dwight Silverman has spearheaded. Kudos to Dwight and the Chronicle editors for being pioneers in this emerging method of delivering their product to customers.
In this post, Mr. Berger notes the National Institutes of Health annual ranking of U.S. medical schools by the amount of research funding, which is a key indicator of a medical school faculty’s research capabilities. Here is a listing of medical schools of local interest:
1. John Hopkins University, Baltimore, Md., $449 million
11. Baylor College of Medicine, $248 million
21. UT Southwestern Med. Center, Dallas, $172 million
35. Cornell Univ. Medical School (Methodist Hospital) $124 million
39. UT Medical Branch at Galveston, $104 million
48. UT Health Science Center at San Antonio, $80 million
64. UT Health Science Center at Houston, $51 million
In addition, although not a medical school, UT’s M.D. Anderson Cancer Center in the Texas Medical Center generated another $145 million in research last year. Consequently, as Mr. Berger notes, the institutions in the Texas Medical Center pump almost half a billion of research funds into the local economy.
By the way, the NIH list dovetails nicely with the ranking of university endowments that was noted in this earlier post. Given the size of Baylor Medical School’s endowment and annual research funding, one has to respect the risk that Baylor took in ending its longtime partnership with the even better-endowed Methodist Hospital ($2.3 billion endowment). Hopefully, the competition between the two institutions for research funds will enhance the amount and quality of research being performed at the Texas Medical Center.